研究单位：[1]Gilead Sciences[2]Tongji Hospital Affiliated to Tongji Medicine University Wuhan, Hubei, China, 430030[3]Xiangyan Hospital, Central South University Changsha, Hunan, China, 410008[4]Shanghai Public Health Clinical Center Hongkou, Shanghai, China, 200083[5]Shanghai Ruijin Hospital Huangpu, Shanghai, China, 200025[6]West China Hospital, Sichuan University Chengdu, Sichuan, China, 610041[7]Peking University First Hospital Beijing, China, 100034[8]Peking University People's Hospital Beijing, China, 100044[9]Beijing Friendship Hospital Affiliate of Capital Medical University Beijing, China, 100050[10]The Second Affiliated Hospital of Chongqing Medical University Chongqing, China, 400010[11]Guangzhou Eighth People's Hospital Guangdong, China, 510060[12]The People's Hospital of Hainan Province Hainan, China, 570311[13]The 2nd Xiangya Hospital of Central South University Hunan, China, 410011[14]The Second Hospital of Nanjing Jiangsu, China, 210003[15]The First Hospital of Jilin University Jilin, China, 130021[16]Beijing Ditan Hospital Chaoyang, Beijing, China, 100015[17]Nanfang Hospital of Southern Medical University Guangzhou, Guangdong, China, 510515[18]The Third Affiliated Hospital, Sun Yat-Sen University Guangzhou, Guangdong, China, 510630[19]The First Affiliated Hospital of Guangxi Medical University Nanning, Guangxi, China, 530021[20]Chulalongkorn Hospital Bangkok, Thailand, 10330[21]Ramathibodi Hospital Mahidol University Bangkok, Thailand, 10400[22]Siriraj Hospital Bankok, Thailand, 10700
研究目的：
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir (SOF)/velpatasvir (VEL; GS-5816) fixed-dose combination (FDC) for 12 weeks in participants with chronic hepatitis C virus (HCV) infection.
